


RealRate

PHARMACEUTICAL 2021



Amphastar Pharmaceuticals Inc. Rank 41 of 409





PHARMACEUTICAL 2021





Amphastar Pharmaceuticals Inc. Rank 41 of 409

The relative strengths and weaknesses of Amphastar Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amphastar Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 351% points. The greatest weakness of Amphastar Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 181% points.

The company's Economic Capital Ratio, given in the ranking table, is 123%, being 478% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	279,682
Cost of Goods Sold	206,506
Intangible Assets	0
Liabilities, Current	112,201
Liabilities, Non-Current	30,676
Other Assets	91,499
Other Compr. Net Income	1,272
Other Expenses	18,320
Other Liabilities	39,636
Other Net Income	-6,317
Property and Equipment	260,055
Research and Development	67,229
Revenues	349,846
Selling, General and Administrative Expense	50,377

Output Variable	Value in 1000 USD
Assets	631,236
Liabilities	182,513
Expenses	342,432
Stockholders Equity	448,723
Net Income	1,097
Comprehensive Net Income	1,733
Economic Capital Ratio	123%